Identification of Moesin (MSN) as a Potential Therapeutic Target for Colorectal Cancer via the β-Catenin-RUNX2 Axis
Abstract
:1. Introduction
2. Results
2.1. MSN Was Found to Be Upregulated in Cancer Tissues and Predicted a Poor Prognosis in CRC Patients
2.2. CRC Cell Growth Was Mediated by MSN Expression
2.3. Cell Cycle Arrest in the G2/M Phase Was Caused by MSN Knockdown
2.4. MSN Knockdown Decreased Adhesion Activity
2.5. MSN Knockdown Decreased CRC Cell Invasion and Migration
2.6. MSN Silencing Reduced RUNX2 Expression in CRC Cells
2.7. MSN Controlled RUNX2 via the Wnt/β-catenin Signaling Pathway
2.8. RUNX2 Silencing Reversed MSN’s Tumor-Promoting Effect in CRC Progression
3. Discussion
4. Materials and Methods
4.1. Chemicals, Reagents, and Cell Culture
4.2. Transfection and Generation of Stable Colonies
4.3. RT-qPCR
4.4. Nuclear/Cytosol Extraction
4.5. Western Blotting
4.6. Cell Proliferation Analysis
4.7. Colony Formation Analysis
4.8. Adhesion Assay
4.9. Cell Cycle Analysis
4.10. Transwell Migration Assay/Invasion Assay
4.11. Wound Healing
4.12. NetworkAnalyst 3.0: A Visual Analytics Platform for Comprehensive Gene Expression Profiling and Meta-Analysis
4.13. Overall Survival, Disease-Free Survival, and Relapse-Free Survival
4.14. cBioPortal Database
4.15. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Ethics Approval and Consent to Participate
Abbreviations
References
- Emons, G.; Spitzner, M.; Reineke, S.; Möller, J.; Auslander, N.; Kramer, F.; Hu, Y.; Beissbarth, T.; Wolff, H.A.; Rave-Fränk, M.; et al. Chemoradiotherapy Resistance in Colorectal Cancer Cells is Mediated by Wnt/beta-catenin Signaling. Mol. Cancer Res. 2017, 15, 1481–1490. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
- Keum, N.; Giovannucci, E. Global burden of colorectal cancer: Emerging trends, risk factors and prevention strategies. Nat. Rev. Gastroenterol. Hepatol. 2019, 16, 713–732. [Google Scholar] [CrossRef] [PubMed]
- Arnold, M.; Sierra, M.S.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global patterns and trends in colorectal cancer incidence and mortality. Gut 2017, 66, 683–691. [Google Scholar] [CrossRef] [Green Version]
- Arnold, M.; Sierra, M.S.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Cancer treatment and survivorship statistics, 2012. CA Cancer J. Clin. 2012, 62, 220–241. [Google Scholar] [CrossRef] [Green Version]
- Sankaranarayanan, R.; Swaminathan, R.; Brenner, H.; Chen, K.; Chia, K.S.; Chen, J.G.; Law, S.C.; Ahn, Y.-O.; Xiang, Y.B.; Yeole, B.B.; et al. Cancer survival in Africa, Asia, and Central America: A population-based study. Lancet Oncol. 2010, 11, 165–173. [Google Scholar] [CrossRef]
- Brenner, H.; Bouvier, A.M.; Foschi, R.; Hackl, M.; Larsen, I.K.; Lemmens, V.; Mangone, L.; Francisci, S. Progress in colorectal cancer survival in Europe from the late 1980s to the early 21st century: The EUROCARE study. Int. J. Cancer. 2012, 131, 1649–1658. [Google Scholar] [CrossRef]
- Brenner, H.; Kloor, M.; Pox, C.P. Colorectal cancer. Lancet 2014, 383, 1490–1502. [Google Scholar] [CrossRef]
- Yamagishi, H.; Kuroda, H.; Imai, Y.; Hiraishi, H. Molecular pathogenesis of sporadic colorectal cancers. Chin. J. Cancer. 2016, 35, 4. [Google Scholar] [CrossRef] [Green Version]
- Marques, R.P.; Duarte, G.; Sterrantino, C.; Pais, H.L.; Quintela, A.; Martins, A.P.; Costa, J. Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis. Crit. Rev. Oncol. Hematol. 2017, 118, 54–62. [Google Scholar] [CrossRef]
- Geng, F.; Wang, Z.; Yin, H.; Yu, J.; Cao, B. Molecular Targeted Drugs and Treatment of Colorectal Cancer: Recent Progress and Future Perspectives. Cancer Biother. Radiopharm. 2017, 32, 149–160. [Google Scholar] [CrossRef]
- Sato, N.; Funayama, N.; Nagafuchi, A.; Yonemura, S.; Tsukita, S.; Tsukita, S. A gene family consisting of ezrin, radixin and moesin. Its specific localization at actin filament/plasma membrane association sites. J. Cell. Sci. 1992, 103 Pt 1, 131–143. [Google Scholar] [CrossRef]
- Schwartz-Albiez, R.; Merling, A.; Spring, H.; Möller, P.; Koretz, K. Differential expression of the microspike-associated protein moesin in human tissues. Eur. J. Cell. Biol. 1995, 67, 189–198. [Google Scholar] [PubMed]
- Bretscher, A.; Edwards, K.; Fehon, R.G. ERM proteins and merlin: Integrators at the cell cortex. Nat. Rev. Mol. Cell Biol. 2002, 3, 586–599. [Google Scholar] [CrossRef] [PubMed]
- Alam, F.; Mezhal, F.; EL Hasasna, H.; A Nair, V.; Aravind, S.; Ayad, M.S.; El-Serafi, A.; Abdel-Rahman, W.M. The role of p53-microRNA 200-Moesin axis in invasion and drug resistance of breast cancer cells. Tumour Biol. 2017, 39, 1010428317714634. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Assao, A.; Yoshino, P.M.; Medeiros, M.C.M.; Carvalho, A.L.; Soares, F.; Kowalski, L.P.; Oliveira, D.T. Moesin Involvement in Oral Carcinogenesis of the Lower Lip. Anticancer. Res. 2018, 38, 2755–2760. [Google Scholar] [CrossRef]
- DeSouza, L.V.; Matta, A.; Karim, Z.; Mukherjee, J.; Wang, X.S.; Krakovska, O.; Zadeh, G.; Guha, A.; Siu, K.M. Role of moesin in hyaluronan induced cell migration in glioblastoma multiforme. Mol. Cancer 2013, 12, 74. [Google Scholar] [CrossRef] [Green Version]
- Hlavaty, J.; Wolfesberger, B.; Hauck, M.; Obermayer-Pietsch, B.; Fuchs-Baumgartinger, A.; Miller, I.; Walter, I. Ezrin and moesin expression in canine and feline osteosarcoma. Histol. Histopathol. 2017, 32, 805–816. [Google Scholar] [CrossRef]
- Hong, H.; Yu, H.; Yuan, J.; Guo, C.; Cao, H.; Li, W.; Xiao, C. MicroRNA-200b Impacts Breast Cancer Cell Migration and Invasion by Regulating Ezrin-Radixin-Moesin. Med. Sci. Monit. 2016, 22, 1946–1952. [Google Scholar] [CrossRef] [Green Version]
- Barros, F.B.A.; Assao, A.; Garcia, N.G.; Nonogaki, S.; Carvalho, A.L.; Soares, F.A.; Kowalski, L.P.; Oliveira, D.T. Moesin expression by tumor cells is an unfavorable prognostic biomarker for oral cancer. BMC Cancer 2018, 18, 53. [Google Scholar] [CrossRef] [Green Version]
- Lan, S.; Zheng, X.; Hu, P.; Xing, X.; Ke, K.; Wang, F.; Cheng, N.; Zhuang, Q.; Liu, X.; Liu, J.; et al. Moesin facilitates metastasis of hepatocellular carcinoma cells by improving invadopodia formation and activating beta-catenin/MMP9 axis. Biochem. Biophys. Res. Commun. 2020, 524, 861–868. [Google Scholar] [CrossRef] [PubMed]
- Pei, X.J.; Xue, X.F.; Zhu, Y.L.; Liu, S.J.; Han, A.J.; Yang, Q.X. Expression and clinical significance of moesin and E-cadherin in invasive carcinoma of breast, no specific type. Zhonghua Bing Li Xue Za Zhi 2016, 45, 550–555. [Google Scholar] [CrossRef] [PubMed]
- Bartova, M.; Hlavaty, J.; Tan, Y.; Singer, C.; Pohlodek, K.; Luha, J.; Walter, I. Expression of ezrin and moesin in primary breast carcinoma and matched lymph node metastases. Clin. Exp. Metastasis 2017, 34, 333–344. [Google Scholar] [CrossRef] [PubMed]
- Wu, Q.; Chen, D.; Luo, Q.; Yang, Q.; Zhao, C.; Zhang, D.; Zeng, Y.; Huang, L.; Zhang, Z.; Qi, Z. Extracellular matrix protein 1 recruits moesin to facilitate invadopodia formation and breast cancer metastasis. Cancer Lett. 2018, 437, 44–55. [Google Scholar] [CrossRef] [PubMed]
- Yu, L.; Zhao, L.; Wu, H.; Zhao, H.; Yu, Z.; He, M.; Jin, F.; Wei, M. Moesin is an independent prognostic marker for ER-positive breast cancer. Oncol. Lett. 2019, 17, 1921–1933. [Google Scholar] [CrossRef] [Green Version]
- Liang, L.; Dong, M.; Cong, K.; Chen, Y.; Ma, Z. Correlations of Moesin expression with the pathological stage, nerve infiltration, tumor location and pain severity in patients with pancreatic cancer. J. Buon. 2019, 24, 1225–1232. [Google Scholar]
- Sikorska, J.; Gaweł, D.; Domek, H.; Rudzińska, M.; Czarnocka, B. Podoplanin (PDPN) affects the invasiveness of thyroid carcinoma cells by inducing ezrin, radixin and moesin (E/R/M) phosphorylation in association with matrix metalloproteinases. BMC Cancer. 2019, 19, 85. [Google Scholar] [CrossRef] [Green Version]
- Wang, Q.; Lu, X.; Wang, J.; Yang, Z.; Hoffman, R.M.; Wu, X. Moesin Up-regulation Is Associated with Enhanced Tumor Progression Imaged Non-invasively in an Orthotopic Mouse Model of Human Glioblastoma. Anticancer Res. 2018, 38, 3267–3272. [Google Scholar] [CrossRef] [Green Version]
- Shin, B.K.; Kim, C.Y.; Jung, W.Y.; Lee, H.J.; Kim, H.K.; Kim, A. Proteomic analysis reveals overexpression of moesin and cytokeratin 17 proteins in colorectal carcinoma. Oncol. Rep. 2012, 27, 608–620. [Google Scholar] [CrossRef] [Green Version]
- Abdou, A.G.; Sakr, S.; Elwahed, M.M.A.; Eladly, E.K. Immunohistochemical assessment of ezrin and moesin in colorectal carcinoma. Ultrastruct. Pathol. 2016, 40, 181–188. [Google Scholar] [CrossRef]
- Cohen, M.M., Jr. Perspectives on RUNX genes: An update. Am. J. Med. Genet. A 2009, 149A, 2629–2646. [Google Scholar] [CrossRef]
- Stein, G.S.; Lian, J.B.; van Wijnen, A.J.; Stein, J.L.; Montecino, M.; Javed, A.; Zaidi, S.K.; Young, D.W.; Choi, J.-Y.; Pockwinse, S.M. Runx2 control of organization, assembly and activity of the regulatory machinery for skeletal gene expression. Oncogene 2004, 23, 4315–4329. [Google Scholar] [CrossRef] [Green Version]
- Yi, H.; Li, G.; Long, Y.; Liang, W.; Cui, H.; Zhang, B.; Tan, Y.; Li, Y.; Shen, L.; Deng, D.; et al. Integrative multi-omics analysis of a colon cancer cell line with heterogeneous Wnt activity revealed RUNX2 as an epigenetic regulator of EMT. Oncogene 2020, 39, 5152–5164. [Google Scholar] [CrossRef]
- Yan, X.; Han, D.; Chen, Z.; Han, C.; Dong, W.; Han, L.; Zou, L.; Zhang, J.; Liu, Y.; Chai, J. RUNX2 interacts with BRG1 to target CD44 for promoting invasion and migration of colorectal cancer cells. Cancer Cell. Int. 2020, 20, 505. [Google Scholar] [CrossRef]
- Slattery, M.L.; Lundgreen, A.; Herrick, J.S.; Caan, B.J.; Potter, J.D.; Wolff, R.K. Associations between genetic variation in RUNX1, RUNX2, RUNX3, MAPK1 and eIF4E and riskof colon and rectal cancer: Additional support for a TGF-β-signaling pathway. Carcinogenesis 2011, 32, 318–326. [Google Scholar] [CrossRef]
- Ji, Q.; Cai, G.; Liu, X.; Zhang, Y.; Wang, Y.; Zhou, L.; Sui, H.; Li, Q. MALAT1 regulates the transcriptional and translational levels of proto-oncogene RUNX2 in colorectal cancer metastasis. Cell. Death Dis. 2019, 10, 378. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chai, J.; Guo, D.; Ma, W.; Han, D.; Dong, W.; Guo, H.; Zhang, Y. A feedback loop consisting of RUNX2/LncRNA-PVT1/miR-455 is involved in the progression of colorectal cancer. Am. J. Cancer Res. 2018, 8, 538–550. [Google Scholar] [PubMed]
- Šuštić, T.; Bosdriesz, E.; van Wageningen, S.; Wessels, L.F.; Bernards, R. RUNX2/CBFB modulates the response to MEK inhibitors through activation of receptor tyrosine kinases in KRAS-mutant colorectal cancer. Transl. Oncol. 2020, 13, 201–211. [Google Scholar] [CrossRef]
- Li, S.-J.; Kao, Y.-H.; Chung, C.-C.; Cheng, W.-L.; Chen, Y.-J. HDAC I inhibitor regulates RUNX2 transactivation through canonical and non-canonical Wnt signaling in aortic valvular interstitial cells. Am. J. Transl. Res. 2019, 11, 744–754. [Google Scholar]
- Zhang, L.; Lu, S.-Y.; Guo, R.; Ma, J.-X.; Tang, L.-Y.; Wang, J.-J.; Shen, C.-L.; Lu, L.-M.; Liu, J.; Wang, Z.-G.; et al. STK10 knockout inhibits cell migration and promotes cell proliferation via modulating the activity of ERM and p38 MAPK in prostate cancer cells. Exp. Ther. Med. 2021, 22, 851. [Google Scholar] [CrossRef] [PubMed]
- Proudfit, A.; Bhunia, N.; Pore, D.; Parker, Y.; Lindner, D.; Gupta, N. Pharmacologic Inhibition of Ezrin-Radixin-Moesin Phosphorylation is a Novel Therapeutic Strategy in Rhabdomyosarcoma. Sarcoma 2020, 2020, 9010496. [Google Scholar] [CrossRef] [PubMed]
- Qin, Y.; Chen, W.; Jiang, G.; Zhou, L.; Yang, X.; Li, H.; He, X.; Wang, H.-L.; Zhou, Y.-B.; Huang, S.; et al. Interfering MSN-NONO complex-activated CREB signaling serves as a therapeutic strategy for triple-negative breast cancer. Sci. Adv. 2020, 6, eaaw9960. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, Q.; Lu, X.; Zhao, S.; Pang, M.; Wu, X.; Wu, H.; Hoffman, R.M.; Yang, Z.; Zhang, Y. Moesin Expression Is Associated with Glioblastoma Cell Proliferation and Invasion. Anticancer Res. 2017, 37, 2211–2218. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Babic, A.; Miladinovic, N.; Milin Lazovic, J.; Milenkovic, S. Decreased ERβ expression and high cyclin D1 expression may predict early CRC recurrence in high-risk Duke’s B and Duke’s C stage. J. Buon. 2021, 26, 536–543. [Google Scholar] [PubMed]
- Xu, J.-M.; Azzariti, A.; Tommasi, S.; Lacalamita, R.; Colucci, G.; Johnston, P.G.; Church, S.W.; Paradiso, A. Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: Clinical relevance. Clin. Color. Cancer 2002, 2, 182–188. [Google Scholar] [CrossRef]
- Wallin, A.; Svanvik, J.; Holmlund, B.; Ferreud, L.; Sun, X.F. Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential. Oncol. Rep. 2008, 19, 1493–1498. [Google Scholar]
- Noordhuis, P.; Laan, A.C.; van de Born, K.; Losekoot, N.; Kathmann, I.; Peters, G.J. Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines. Biochem. Pharmacol. 2008, 76, 53–61. [Google Scholar] [CrossRef]
- Hu, T.; Li, Z.; Gao, C.-Y.; Cho, C.H. Mechanisms of drug resistance in colon cancer and its therapeutic strategies. World J. Gastroenterol. 2016, 22, 6876–6889. [Google Scholar] [CrossRef]
- Dallas, N.A.; Xia, L.; Fan, F.; Gray, M.J.; Gaur, P.; van Buren, G., II; Samuel, S.; Kim, M.P.; Lim, S.J.; Ellis, L.M. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res. 2009, 69, 1951–1957. [Google Scholar] [CrossRef] [Green Version]
- Alamoud, K.A.; Kukuruzinska, M.A. Emerging Insights into Wnt/β-catenin Signaling in Head and Neck Cancer. J. Dent. Res. 2018, 97, 665–673. [Google Scholar] [CrossRef]
- Arend, R.C.; Londoño-Joshi, A.I.; Straughn, J.M., Jr.; Buchsbaum, D.J. The Wnt/β-catenin pathway in ovarian cancer: A review. Gynecol. Oncol. 2013, 131, 772–779. [Google Scholar] [CrossRef]
- Guichard, C.; Amaddeo, G.; Imbeaud, S.; Ladeiro, Y.; Pelletier, L.; Maad, I.B.; Calderaro, J.; Bioulac-Sage, P.; Letexier, M.; Degos, F.; et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat. Genet. 2012, 44, 694–698. [Google Scholar] [CrossRef]
- Bass, A.J.; Thorsson, V.; Shmulevich, I.; Reynolds, S.M.; Miller, M.; Bernard, B.; Hinoue, T.; Laird, P.W.; Curtis, C.; Shen, H.; et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014, 513, 202–209. [Google Scholar] [CrossRef] [Green Version]
- Robinson, D.; Van Allen, E.M.; Wu, Y.-M.; Schultz, N.; Lonigro, R.J.; Mosquera, J.-M.; Montgomery, B.; Taplin, M.-E.; Pritchard, C.C.; Attard, G.; et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015, 161, 1215–1228. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bahrami, A.; Amerizadeh, F.; ShahidSales, S.; Khazaei, M.; Ghayour-Mobarhan, M.; Sadeghnia, H.R.; Maftouh, M.; Hassanian, S.M.; Avan, A. Therapeutic Potential of Targeting Wnt/β-Catenin Pathway in Treatment of Colorectal Cancer: Rational and Progress. J. Cell Biochem. 2017, 118, 1979–1983. [Google Scholar] [CrossRef] [PubMed]
- Clevers, H.; Loh, K.M.; Nusse, R. Stem cell signaling. An. integral program for tissue renewal and regeneration: Wnt signaling and stem cell control. Science 2014, 346, 1248012. [Google Scholar] [CrossRef] [PubMed]
- Basu, S.; Haase, G.; Ben-Ze’ev, A. Wnt signaling in cancer stem cells and colon cancer metastasis. F1000Research 2016, 5, 699. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Muzny, D.M.; Bainbridge, M.N.; Chang, K.; Dinh, H.H.; Drummond, J.A.; Fowler, G.; Kovar, K.L.; Lewis, L.R.; Morgan, M.B.; Newsham, I.F.; et al. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487, 330–337. [Google Scholar] [CrossRef] [Green Version]
- Ji, M.; Fan, D.; Yuan, L.; Zhang, Y.; Dong, W.; Peng, X. EBP50 inhibits pancreatic cancer cell growth and invasion by targeting the β-catenin/E-cadherin pathway. Exp. Ther. Med. 2015, 10, 1311–1316. [Google Scholar] [CrossRef] [Green Version]
- Peng, K.; Su, G.; Ji, J.; Yang, X.; Miao, M.; Mo, P.; Li, M.; Xu, J.; Li, W.; Yu, C. Histone demethylase JMJD1A promotes colorectal cancer growth and metastasis by enhancing Wnt/β-catenin signaling. J. Biol. Chem. 2018, 293, 10606–10619. [Google Scholar] [CrossRef] [Green Version]
- Yang, X.-Z.; Cui, S.-Z.; Zeng, L.-S.; Cheng, T.-T.; Li, X.-X.; Chi, J.; Wang, R.; Zheng, X.S.; Wang, H.-Y. Overexpression of Rab1B and MMP9 predicts poor survival and good response to chemotherapy in patients with colorectal cancer. Aging 2017, 9, 914–931. [Google Scholar] [CrossRef] [Green Version]
- Wang, J.; Cai, H.; Liu, Q.; Xia, Y.; Xing, L.; Zuo, Q.; Zhang, Y.; Chen, C.; Xu, K.; Yin, P.; et al. Cinobufacini Inhibits Colon Cancer Invasion and Metastasis via Suppressing Wnt/β-Catenin Signaling Pathway and EMT. Am. J. Chin. Med. 2020, 48, 703–718. [Google Scholar] [CrossRef] [PubMed]
- Banday, M.Z.; Sameer, A.S.; Mir, A.H.; Mokhdomi, T.A.; Chowdri, N.A.; Haq, E. Matrix metalloproteinase (MMP) -2, -7 and -9 promoter polymorphisms in colorectal cancer in ethnic Kashmiri population—A case-control study and a mini review. Gene 2016, 589, 81–89. [Google Scholar] [CrossRef] [PubMed]
- Wei, P.L.; Lin, J.C.; Hung, C.S.; Makondi, P.T.; Batzorig, U.; Chang, T.C.; Huang, C.Y.; Chang, Y.J. Human α-defensin 6 (HD6) suppresses CRC proliferation and metastasis through abolished EGF/EGFR signaling pathway. Int. J. Med. Sci. 2022, 19, 34–46. [Google Scholar] [CrossRef] [PubMed]
- Zhou, G.; Soufan, O.; Ewald, J.; Hancock, R.E.W.; Basu, N.; Xia, J. NetworkAnalyst 3.0: A visual analytics platform for comprehensive gene expression profiling and meta-analysis. Nucleic Acids Res. 2019, 47, W234–W241. [Google Scholar] [CrossRef] [Green Version]
- Szklarczyk, D.; Franceschini, A.; Wyder, S.; Forslund, K.; Heller, D.; Huerta-Cepas, J.; Simonovic, M.; Roth, A.; Santos, A.; Tsafou, K.P.; et al. STRING v10: Protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015, 43, D447–D452. [Google Scholar] [CrossRef] [Green Version]
- Park, S.-J.; Yoon, B.-H.; Kim, S.-Y. GENT2: An updated gene expression database for normal and tumor tissues. BMC Med. Genomics. 2019, 12 (Suppl. 5), 101. [Google Scholar] [CrossRef]
- Cerami, E.; Gao, J.; Dogrusoz, U.; Gross, B.E.; Sumer, S.O.; Aksoy, B.A.; Jacobsen, A.; Byrne, C.J.; Heuer, M.L.; Larsson, E.; et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012, 2, 401–404. [Google Scholar] [CrossRef] [Green Version]
- Cerami, E.; Gao, J.; Dogrusoz, U.; Gross, B.E.; Sumer, S.O.; Aksoy, B.A.; Jacobsen, A.; Byrne, C.J.; Heuer, M.L.; Larsson, E.; et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal 2013, 6, pl1. [Google Scholar] [CrossRef] [Green Version]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Huang, C.-Y.; Wei, P.-L.; Batzorig, U.; Makondi, P.T.; Lee, C.-C.; Chang, Y.-J. Identification of Moesin (MSN) as a Potential Therapeutic Target for Colorectal Cancer via the β-Catenin-RUNX2 Axis. Int. J. Mol. Sci. 2023, 24, 10951. https://doi.org/10.3390/ijms241310951
Huang C-Y, Wei P-L, Batzorig U, Makondi PT, Lee C-C, Chang Y-J. Identification of Moesin (MSN) as a Potential Therapeutic Target for Colorectal Cancer via the β-Catenin-RUNX2 Axis. International Journal of Molecular Sciences. 2023; 24(13):10951. https://doi.org/10.3390/ijms241310951
Chicago/Turabian StyleHuang, Chien-Yu, Po-Li Wei, Uyanga Batzorig, Precious Takondwa Makondi, Cheng-Chin Lee, and Yu-Jia Chang. 2023. "Identification of Moesin (MSN) as a Potential Therapeutic Target for Colorectal Cancer via the β-Catenin-RUNX2 Axis" International Journal of Molecular Sciences 24, no. 13: 10951. https://doi.org/10.3390/ijms241310951